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Genome editing using clustered regularly interspersed
short palindromic repeats (CRISPR) and CRISPR-associated
proteins offers the potential to facilitate safe and effective
treatment of genetic diseases refractory to other types
of intervention. Here, we identify some of the major
challenges for clinicians, regulators, and human research
ethics committees in the clinical translation of CRISPR-
mediated somatic cell therapy.are yet to fully address. We posit that these regulatoryRegulatory challenges for CRISPR-mediated somatic
cell therapy
The discovery that clustered regularly interspersed short
palindromic repeats (CRISPR) and CRISPR-associated
proteins found naturally in prokaryotic cells can be used
to alter the genome of living organisms—including
humans—has been one of the most exciting break-
throughs in biomedical science. Perhaps unsurprisingly,
commentary on the ethical, social, and legal implications
has focused primarily on concerns that, in the future,
the technology could be used to heritably edit human
germ cells, creating “designer babies”.
The current intense focus on germline genome
editing—while it is understandable and necessary—diverts
attention away from other pressing issues associated with
clinical delivery in the non-germline context, where only
the treated individual is affected. Given that attempts are
already being made to use CRISPR-mediated somatic cell* Correspondence: Dianne.Nicol@utas.edu.au
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refractory to traditional therapies, somatic genome editing
is an arguably more pressing issue [1].
Here we consider the regulatory conditions that need
to be clarified for the medical community and the wider
public to feel confident about moving somatic genome
editing from bench to bedside. The regulatory parame-
ters must be strong enough to engender confidence yet
sufficiently flexible to respond to technological and so-
cial developments; a challenge that most jurisdictions
parameters should ideally be consistent globally, to pro-
vide greater certainty for the rapidly expanding industry
and consistent safeguards for recipients. However, we
recognize the almost insurmountable hurdles involved in
achieving this end.Refocusing CRISPR law and ethics towards the
clinic
There has been some progress towards identifying core
principles to guide the responsible development and use
of somatic genome editing. A report by the US National
Academies [2] and a preliminary report by the UK
Nuffield Council on Bioethics [3] both made important
contributions in this regard. Notably, the US report con-
cluded that current regulatory processes are adequate in
the context of somatic cell therapies. However, this
ignores the fact that CRISPR, in particular, and emergent
personalized somatic cell therapies, in general, pose a
range of challenges for regulators. Table 1 provides a
non-exhaustive list of specific regulatory uncertainties
that require attention; they are not necessarily new, nor
are they specific to CRISPR. For instance, the firstle is distributed under the terms of the Creative Commons Attribution 4.0
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Table 1 Issues in applying existing review and approval processes to clustered regularly interspersed short palindromic repeats
(CRISPR)-mediated genome editing
Approval pathway Issues to be resolved
Drugs and medical devices Medical products generally go through some form of pre-market assessment to demonstrate clinical utility,
safety, and efficacy. Many jurisdictions have developed adaptive licensing schemes including “fast track”
approval, hospital exemptions, and compassionate use provisions that permit accelerated access to innovative
treatments where they address unmet clinical need. These schemes can be invaluable in building up an early
evidence base for promising but disruptive interventions, as many clinical CRISPR applications are likely to be,
but at present there is little coordination across jurisdictions about the criteria to access these schemes or
recognition of the evidence they generate.
Medical procedures There is ambiguity over whether CRISPR-mediated genome-editing technology is characterized as a medical
product or procedure. This means it is unclear whether pre-market approval is required or whether, like surgical
procedures, early assessment should be governed by domestic professional societies and institutional funding.
Patient-tailored precision
therapies
The high variability of biological manufacturing processes, where each batch can effectively be considered a
separate product, and the individual patient-focused nature of many cell and gene therapies challenges the
reliance on large-scale double-blind, placebo-controlled randomized controlled trials as the most relevant
model for producing evidence of clinical safety and efficacy. A significant issue for CRISPR is whether patient-
specific CRISPR constructs would each require separate approval or whether constructs with common
characteristics can be treated as a group.
Exempted products Not all medical products require regulatory approval. The exemption of human tissues and cells collected from
patients and returned to them after ex vivo treatment is one example. This exemption could, at least theoretically,
extend to certain CRISPR applications.
Public versus private funding Different levels of protection may apply depending on whether the application is being developed by a publicly
or privately funded institution. In the United States, for example, submission of gene therapy proposals to the
recombinant DNA advisory committee (RAC) is only mandatory for research conducted at institutions receiving
National Institutes of Health funding. For gene therapy at private institutions, submission to the RAC is voluntary.
As public–private consortia become common tools for facilitating translational medicine, hard regulatory
boundaries between public and private actors are likely to stifle innovation rather than secure safety.
Technology-specific regulation Many nations have specific regulatory requirements for research involving transfer of genes (e.g., the RAC in the
United States, and the Office of the Gene Technology Regulator in Australia). Designed to respond to technological
capabilities as they existed at the point of enactment, these laws do not necessarily address the demands of
fast-paced developments. In Europe, for example, there is confusion as to whether CRISPR-engineered organisms
count as “genetically modified organisms”. Different European Union Member States classify clinical gene therapies
as either “contained use” or “deliberate release” of a genetically modified organism, meaning the same procedure
can be subject to different interpretations of the same European Union rules in different territories.
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keting in 2016, following prolonged clinical trials
starting in 2000 [4]. Many other gene and regenera-
tive therapies are also currently under trial. The
emergence and rapid uptake of CRISPR, and the
promise it holds in the delivery of a broader range of
somatic cell therapies, makes the discussion around
the need to resolve regulatory uncertainities more
pressing than ever.
Responses to the regulatory uncertainties outlined in
Table 1 need to be nuanced and flexible. The dangers of
overly rigid regulatory responses to emerging technolo-
gies (e.g., through “command and control” legislation)
have been demonstrated; for example, Canadian and
Australian legislative responses to reproductive cloning,
15 years on, prevent scientists from undertaking work
on some forms of mitochondrial transfer in those
countries, irrespective of the potential benefits. Given
the difficulty in future-proofing, mechanisms for
periodic review need to be included to ensure respon-
siveness to evolving understanding of novel technologies
and re-evaluation of their harms and benefits. This mayhelp to prevent prematurely locking in regulatory
parameters, which can otherwise remain untouched for
generations, as has happened with the US Common Rule
[5]. In the context of genome editing, and of any other
emergent personalized therapy, regulation must be
sufficiently flexible and technologically adaptive to ad-
dress new technological advances and applications as
they arise.
Broader stakeholder engagement in risk
assessment
Quantifying the likely harms and benefits of novel,
disruptive therapeutics such as genome editing will
always involve considerable uncertainty. Within the
permissible spectrum of CRISPR-mediated activities,
rigorous regulatory approaches for risk and benefit as-
sessment will be essential. This is not to assert that all
regulatory insufficiencies require probing evaluations of
their specific applicability and adequacy in respect of
genome editing. Jurisdictions may legitimately set different
thresholds for an acceptable risk–benefit ratio. Nonethe-
less, several features of any assessment process should be
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must be grounded in adequate scientific expertise, but
take into account social as well as technical aspects
of risk.
We argue that it will be challenging for clinicians
or regulatory agencies to navigate the risks and bene-
fits of translating genome editing into the clinic by
relying on expert judgement alone, and that broader
consultation is required. Trials of CRISPR-mediated
somatic cell therapies present an opportunity to
engage a wider range of stakeholders, especially pa-
tients and patient groups, in determining the accept-
able thresholds for risk and benefit. Ideally, this
means not only considering what magnitude of risk is
acceptable, but discussing which outcomes are taken
into consideration, and what counts as harm or bene-
fit, and to whom [6].
Regulators have traditionally shown reluctance to
engage widely in the course of their risk–benefit assess-
ments. National regulators of medical products, for
example, often operate in conditions of secrecy, with the
European Medicines Agency, the Japanese Pharmaceuti-
cals and Medical Devices Agency, and the Australian
Therapeutic Good Administration typically only publish-
ing information about product reviews and the evidence
on which they rest after they have made made their
decision. By contrast, US Food and Drug Administration
Advisory Committee meetings are open to public
participation.
Human research ethics committees, which take re-
sponsibility for approving and monitoring clinical trials
in most countries, present a greater opportunity for
broad engagement. They are generally required to have a
diverse membership base, including members who are
not trained in science. Nonetheless, medical and scien-
tific members have consistently been assessed as having
a greater influence on committee decision-making than
others, even where community-wide ethical issues are
present [7]. And astonishingly, some research ethics
codes (e.g., the US Common Rule [5]) expressly prohibit
considering the potential long-term social implications
of a research project.
Some programmes, such as the European Patients’
Academy on Therapeutic Innovation and the US Pro-
fessional Patient Advocate Institute provide training
and support to enable patients to engage as advocates
in the drug discovery process. But it remains unclear
whether there will be longer-term institutional
support for more direct involvement of patients and
their representatives [8]. Incorporating improved
public and stakeholder engagement mechanisms will
assist in future-proofing regulation. More work needs
to be done to develop appropriate mechanisms for
open and inclusive multi-stakeholder dialogue.Financial and intellectual property imperatives
Another complication in the further clinical development
of CRISPR technology is the need to ensure that the finan-
cial benefits of clinical delivery outweigh the costs.
One way to reduce the large financial burdens associ-
ated with medical product reviews and approvals is to
harmonize processes across countries. This means that if
an approval is gained in one country, the same evidence
can be used for approval in another (and perhaps even
be automatically granted). Such harmonization would
permit product development companies to reach
economies of scale more quickly, reducing the cost of
medical products and resulting in more favorable cost–
benefit analyses. Although international harmonization
is difficult to achieve, regulators should continue to work
towards this goal, and considerable efforts have already
been made in this regard.
Reimbursement is also a significant consideration.
There are different national systems for evaluating
whether a given intervention has adequate cost–benefit
returns to make it worth paying for. This, when
conducted by bodies like the UK National Institute for
Health and Clinical Excellence, is sometimes regarded as
the “fourth hurdle” of regulation. Glybera, the first gene
therapy product to get European marketing authorization
and approval, has recently been discontinued by its manu-
facturers following poor uptake by physicians resulting
from cost recovery issues [9].
Patent rights add yet another layer of complexity. The
development of any new technology generally prompts a
raft of patent filings. In the case of genome editing this
has been accompanied by a prolonged patent dispute,
which has implications for both commercial and clinical
applications. To date, this dispute has been resolved dif-
ferently in Europe and the United States, although
further judicial proceedings are likely in both jurisdictions.
Issues surrounding patent ownership and validity feed
into clinical delivery. After all, a product will only be
developed and marketed if there is some prospect of
recouping research and development costs. The tempor-
ary exclusivity provided by patents can facilitate this.
Patents can also be used as tools to minimize social
harm and maximize social benefit if owners are able to
negotiate ethical terms into patent license agreements.
By contrast, delegation by owners to a small number of
surrogate licensors—who may themselves be in competi-
tion with other developers—has the potential to create
bottlenecks in rapidly developing fields [10]. In addition,
patent licenses that incorporate significantly different
terms for public and private end users may cause prob-
lems for academic–industry partnerships working to
develop innovative CRISPR therapeutics. Ambiguities in
the patent landscape surrounding CRISPR are likely to
further confuse clinical translation pathways.
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New technologies—and CRISPR-mediated genome edit-
ing in particular—often elicit a plethora of ethical, med-
ical, and commercial questions from a variety of
stakeholders, raising regulatory and social challenges.
This is the case both in areas where there are overlap-
ping regulatory obligations (regulatory congestions) and
in areas where there is an absence of regulation (regula-
tory gaps) [11]. But focusing on any technology’s extre-
mes—especially where “worst case scenarios” are
unrealistic or technologically impractical—often results
in rigid, top-down approaches, prone to be reactive and
piecemeal. Focusing on regulatory issues in somatic—rather
than germline—genome editing applications is of more
immediate benefit to patients and highlights the gaps and
congestions in most urgent need of attention.
Here, we have identified key areas of regulatory confu-
sion that are likely to impede the process of translating
somatic genome editing to the clinic. Resolving these
issues will encourage the development and approval of
applications that are both clinically robust—safe,
efficient, and for the benefit of patients—and socially
robust—accountable, democratic, and trustworthy.
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